Fibrinolysis in Intermediate-Risk PE Between Prevention and Risk – Unidad de ETV Hospital Gregorio Marañón
Unidad de ETV Hospital Gregorio Marañón shared a post on X about a recent article by Eva Cervilla-Muñoz et al., published in Journal of Clinical Medicine:
“The use of systemic fibrinolysis in intermediate-risk PE remains one of the great clinical debates: Prevent hemodynamic deterioration or assume greater hemorrhagic risk?
In our new article, conducted together with CardioHGUGM, we analyze a real-world cohort.”
Title: Systemic Fibrinolysis in Symptomatic Intermediate-Risk Pulmonary Embolism: A Real-World Cohort Study
Authors: Eva Cervilla-Muñoz, Pablo Demelo-Rodríguez, Rubén Alonso-Beato, Miriam Juárez-Fernández, Iago Sousa-Casasnovas, Lucía Ordieres-Ortega, Marina López-Rubio, Luis-Antonio Alvarez-Sala Walther, Francisco Galeano-Valle
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 14, 2026, 06:26Delivering Gene Therapy in Hemophilia – ISTH
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials